The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure

British Journal of General Practice

Volumn 56, Issue 526, 2006, Pages 327-333

  Fuat, Ahmet ^a,b,c,d   Murphy, Jeremy J ^a   Hungin, A Pali S ^b   Curry, Jane ^a   Mehrzad, Ali A ^e   Hetherington, Andrew ^e,f   Johnson, Jennifer J ^g   Smellie, W Stuart A ^g   Duffy, Victoria ^c   Cawley, Patricia ^f  

^a DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c Darlington Primary Care Trust   (United Kingdom)

^d Bishop Auckland General Hospital ^*  (United Kingdom)

^e BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^f Durham Dales Primary Care Trust   (United Kingdom)

^g Bunny Hill Primary Care Centre   (United Kingdom)

Author keywords

Diagnosis; Heart failure; Natriuretic paptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; FEMALE; GENERAL HOSPITAL; GENERAL PRACTICE; GENERAL PRACTITIONER; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PATIENT SELECTION; POPULATION RESEARCH; PREDICTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; ECHOCARDIOGRAPHY; FAMILY PRACTICE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646571538     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Wheeldon NM, MacDonald TM, Flucker CJ, et al. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86: 17-23.
2. Remes J, Miettinen H, Reunanen A, et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-321.
3. Khunti K. Systematic review of open access echocardiography for primary care. Eur J Heart Fail 2004; 6: 79-83.
4. Fuat A, Hungin APS, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003; 326: 196-200.
5. Rimington H, Adam G, Chambers J. Open access echocardiography. Lancet 1996; 348: 555-556.
6. Hobbs FDR, Jones MI, Allan TF, et al. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J 2000; 21: 1877-1887.
7. Yasue H, Yoshimura M, Sumidan H, et al. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
8. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
9. Groenning BA, Nilsson JC, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohormonal plasma concentrations. Eur J Heart Fail 2001; 3: 699-708.
10. Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990; 323: 757-758.
11. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-1718.
12. National Institute for Clinical Excellence. Chronic Heart Failure. Clinical Guideline No.5. London: National Institute for Clinical Excellence, 2003.
13. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
14. Cowie MR, Struthers AD, Woods DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-1353.
15. Smith H, Pickering RM, Struthers AD, et al. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ 2000; 320: 906-908.
16. Hobbs FD, Davis RC, Roalfe AK, et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324: 1498-1502.
17. McClure SJ, Caruana L, Davie AP, et al. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998; 317: 516-519.
18. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular dysfunction in general practice: cross sectional study. BMJ 2000; 320: 985-986.
19. Hetmanski DJ, Sparrow NJ, Curtis S, et al. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart 2000; 84: 440-441.
20. Fuat A, Murphy JJ, Hungin APS. Designing heart failure services: a primary care perspective? Heart 2003; 89: A11.
21. Hanley JA, McNeil BJ. The meaning and use of the area under the receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
22. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
23. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc of Echocardiogr 1989, 2: 358-367.
24. Willenheimer RB, Israelsson BA, Cline CM, Erhardt LR. Simplified echocardiography in the diagnosis of heart failure. Scand Cardiovasc J 1997; 31: 9-16.
25. Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-677.
26. Rose GA, Blackburn H. The Minnesota Criteria. Cardiovascular survey methods. World Health Organisation Monograph Series No. 56. Geneva: World Health Organisation, 1956.
27. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
28. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide (BNP) in diagnosing diastolic dysfunction. Circulation 2002; 105: 595-601.
29. Bettencourt P, Ferreira A, Sousa T, et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol 1999; 69: 169-177.
30. Rossi A, Enriquez-Sarano M, Burnett JC, et al. Natriuretic peptide levels in atrial fibrillation. J Am Coll Cardiol 2000; 35: 1256-1262.
31. Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725-732.
32. Bando M, Ishii Y, Sugiyama Y, et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93: 507-514.
33. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
34. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39: 1623-1629.
35. Brunner-La Rocca HP, Weilenmann D, Kiowski W, et al. Within patient comparison of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 1999; 138: 654-662.
36. Fung JW, Yu CM, Yip G, et al. Effect of beta-blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003; 92: 406-410.
37. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides and mortality in an urban population. Heart 2001; 86: 21-26.
38. Tsutamoto T, Wada A, Maeda K, et al. Attenuation and compensation of endogenous cardiac natriuretic peptide system in chronic heart failure - prognostic role of brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
39. Latini R, Maason S, Anand I, et al. The comparative prognostic value of plasma neurohormones baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 281-282.
40. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results of the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41: 2018-2021.
41. Murdoch DR, Byrne J, Morton JJ, et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997; 78: 594-597.
42. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312: 222.
43. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart failure diagnosis in primary care. J Am Coll Cardiol 2003; 42: 1793-1800.